The Miltenyi Bioindustry team of process, analytical, and manufacturing experts leverages decades of experience in lentiviral vector (LVV) production and cell and gene therapy (CGT) manufacturing. Our scalable LVV production platform, as well as our CliniMACS Prodigy® Platform for cell manufacturing, are the foundation for high quality CGT products. We are able to progress client projects through all steps, ranging from early development through to commercial manufacturing.
Our extensive experience includes the generation of engineered immune cells and hematopoietic stem cells (HSCs), immune cells for adoptive transfer, and the expansion and differentiation of pluripotent stem cells (PSCs) and mesenchymal stem cells (MSCs). A broad range of clinically relevant applications in cell processing enables both autologous and allogeneic therapies. Together with our clients, we build tailored and lasting solutions to strengthen clinical programs on the way to advanced therapy success.
These are generated from a variety of starting materials, such as leukapheresis, bone marrow, peripheral blood, cord blood, or tumor tissue.
For cell processing, we rely on our CliniMACS Prodigy Platform